Abstract
In the past decade, cancer stem cells (CSCs) have been isolated, characterized, and studied in a variety of cancers and they are believed to be responsible for tumor initiation and progression. Like normal stem cells, these cells retain self-renewal property and therefore, can differentiate into multiple tumor types. Despite this clinical importance, how CSCs are regulated and their exact pathological role are yet to be elucidated. Recent studies have shed light on the potential role of miRNAs in regulating CSCs. In this review, we summarize the current findings of miRNAs in the regulation of CSCs through different self-renewal pathways and the potential therapeutic implications of miRNAs in clinical settings by targeting CSCs.
Keywords: Cancer stem cells, MicroRNA, signaling pathways, self-renewal.
Current Pharmaceutical Design
Title:MicroRNAs in Cancer Stem Cells: New Regulators of Stemness
Volume: 20 Issue: 33
Author(s): Fei Xing, Kerui Wu and Kounosuke Watabe
Affiliation:
Keywords: Cancer stem cells, MicroRNA, signaling pathways, self-renewal.
Abstract: In the past decade, cancer stem cells (CSCs) have been isolated, characterized, and studied in a variety of cancers and they are believed to be responsible for tumor initiation and progression. Like normal stem cells, these cells retain self-renewal property and therefore, can differentiate into multiple tumor types. Despite this clinical importance, how CSCs are regulated and their exact pathological role are yet to be elucidated. Recent studies have shed light on the potential role of miRNAs in regulating CSCs. In this review, we summarize the current findings of miRNAs in the regulation of CSCs through different self-renewal pathways and the potential therapeutic implications of miRNAs in clinical settings by targeting CSCs.
Export Options
About this article
Cite this article as:
Xing Fei, Wu Kerui and Watabe Kounosuke, MicroRNAs in Cancer Stem Cells: New Regulators of Stemness, Current Pharmaceutical Design 2014; 20 (33) . https://dx.doi.org/10.2174/1381612820666140128210912
DOI https://dx.doi.org/10.2174/1381612820666140128210912 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Roles of SM22α in Cellular Plasticity and Vascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets Potential Targets of P. acnes for New Treatments of P. acnes-Associated Diseases
Current Proteomics The Ultrasonographic Diagnosis of Polycystic Ovary Syndrome
Current Medical Imaging Meet Our Editorial Board Member:
Current Pharmaceutical Design Recurrence in Bladder Cancer: A Molecular Dead End?
Current Genomics Recent Development of Copolymeric Delivery System for Anticancer Agents Based on Cyclodextrin Derivatives
Anti-Cancer Agents in Medicinal Chemistry Curcumin and its Formulations: Potential Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Role of Genetic Factors in the Pathogenesis of Radial Deficiencies in Humans
Current Genomics Developing Histone Deacetylase Inhibitors as Anti-Cancer Therapeutics
Current Medicinal Chemistry Nanoparticle Based Delivery of Protease Inhibitors to Cancer Cells
Current Medicinal Chemistry Experimental and Computational Insights into Bis-indolylmethane Derivatives as Potent Antimicrobial Agents Inhibiting 2,2-dialkylglycine Decarboxylase
Current Enzyme Inhibition The Epithelial-Mesenchymal Transition and Cancer Stem Cells: Functional and Mechanistic Links
Current Pharmaceutical Design Adenosine and the Auditory System
Current Neuropharmacology The Anticancer Properties of Silibinin: Its Molecular Mechanism and Therapeutic Effect in Breast Cancer
Anti-Cancer Agents in Medicinal Chemistry Review of the Contribution of Radiolabelled Tracers for Tumour Cell Status Imaging
Current Medical Imaging New Potential Serum Biomarkers in Multiple Sclerosis Identified by Proteomic Strategies
Current Medicinal Chemistry Theranostic Radiopharmaceuticals Targeting Cancer-Associated Fibroblasts
Current Radiopharmaceuticals Prostaglandin E<sub>2</sub> Receptor 4 (EP4): A Promising Therapeutic Target for the Treatment of Cancer and Inflammatory Diseases
Current Chemical Biology Anal Carcinoma
Current Cancer Therapy Reviews Anti-tumor Drug Targets Analysis: Current Insight and Future Prospect
Current Drug Targets